Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Buprenorphine Market size was valued at USD 6.22 billion in 2024 and is expected to reach USD 35.75 billion by 2037, expanding at around 14.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of buprenorphine is assessed at USD 6.98 billion.
The growth of the market can be attributed to the growing prevalence of chronic pain disorders, increasing occurrence of cancer. According to the World Health Organization (WHO), cancer is the leading cause of deaths worldwide, accounting to about 10 million deaths in the year 2020. In addition to these, escalating government investments in healthcare in developed nations and rising usage of buprenorphine patches as an effective treatment mode is also anticipated to drive market growth in the coming years. Furthermore, the growing dependency on painkillers has led to opioid addiction to many people around the world, which in turn is projected to provide lucrative opportunities to significantly raise the demand for buprenorphine in the near future.
Buprenorphine Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Occurrence of Chronic Pain Disorders
- Rising Healthcare Expenditure in Developed Nations
Challenges
- Adverse Health Effects Associated with the Use of Buprenorphine
Buprenorphine Segmentation
The market is segmented by route of administration into sublingual, transdermal, and buccal, out of which, the sublingual segment is anticipated to hold the largest share in the buprenorphine market on account of the increasing availability of buprenorphine drugs in several dosages in the sublingual form. Along with this, rapid drug absorption, first-pass metabolism and quick onset of action of sublingual route of administration are also predicted to boost the growth of the market segment in the forecast period. Additionally, the segment for buccal dosage is expected to witness notable growth in the future, which can be credited to the increasing number of people opting for oral drugs as compared to injection-based drugs.
Our in-depth analysis of the global market includes the following segments
|
By Route Of Administration
|
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBuprenorphine Industry - Regional Synopsis
North America Market Statistics
On the basis of geographical analysis, the market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is set to account for largest revenue share by 2037, on the back of strong presence of market players and growing percentage of the population suffering from opioid dependency in the region. As per the data by National Institute of Drug Abuse, 21 to 29 percent of patients misuse the opioids prescribed for chronic pain. Amongst these, 8-12% people develop an opioid use disorder. Apart from these, high number of cases of abuse related to drugs such as heroin and cocaine is also anticipated to drive the region’s market growth in the forthcoming years.
Europe Market Analysis
Europe is also expected to acquire a notable share in the market owing to the large number of new medical product launches in the region. Moreover, the market in Asia Pacific is projected to witness noteworthy growth during the forecast period ascribing to the rising patient pool and growing awareness about the health benefits of buprenorphine in the region.
Companies Dominating the Buprenorphine Landscape
- The Siegfried Group, LLP
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Johnson Matthey Group
- Purdue Pharma LP
- Pharmaforce Inc.
- Hikma Pharmaceuticals PLC
- Bedford Laboratories
- Sun Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Neon Laboratories Ltd.
- Unichem Laboratories
In the News
· June 2021: Purdue Pharma LP announced that FDA accepted and filing of the abbreviated new drug application for vial dosage form of nalmefene hydrochloride injection, which is designed to treat opioid overdose.
· May 2020: Hikma Pharmaceuticals PLC launched Buprenorphine Hydrochloride Injection, 0.3mg/mL in the United States through its American affiliate
Author Credits: Radhika Pawar
- Report ID: 3193
- Published Date: Dec 26, 2024
- Report Format: PDF, PPT
